Alterity Therapeutics Ltd
ATHE3.848USD
-0.052-1.33%
Market hours （ET）Quotes delayed by 15 min
58.54MMarket Cap
--P/E TTM
More Details of Alterity Therapeutics Ltd Company
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.
Alterity Therapeutics Ltd Info
Ticker SymbolATHE
Company nameAlterity Therapeutics Ltd
IPO dateMar 28, 2000
CEODr. David A. Stamler, M.D.
Number of employees9
Security typeDepository Receipt
Fiscal year-endMar 28
AddressL 3 460 Bourke St
CityMELBOURNE
Stock exchangeNASDAQ Capital Market Consolidated
CountryAustralia
Postal code3000
Phone61393494906
Websitehttps://alteritytherapeutics.com/
Ticker SymbolATHE
IPO dateMar 28, 2000
CEODr. David A. Stamler, M.D.
Company Executives of Alterity Therapeutics Ltd
Name
Name/Position
Position
Shareholding
Change
Ms. Abby Macnish Niven
Ms. Abby Macnish Niven
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
--
--
Mr. Lawrence B. Gozlan
Mr. Lawrence B. Gozlan
Non-Executive Director
Non-Executive Director
--
--
Mr. Peter Ashley Marks
Mr. Peter Ashley Marks
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Brian Derek Meltzer
Mr. Brian Derek Meltzer
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Hannah Howlett
Ms. Hannah Howlett
Investor Relations
Investor Relations
--
--
Mr. Geoffrey Paul Kempler
Mr. Geoffrey Paul Kempler
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Dr. David A. Stamler, M.D.
Dr. David A. Stamler, M.D.
Chief Executive Officer
Chief Executive Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Abby Macnish Niven
Ms. Abby Macnish Niven
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
--
--
Mr. Lawrence B. Gozlan
Mr. Lawrence B. Gozlan
Non-Executive Director
Non-Executive Director
--
--
Mr. Peter Ashley Marks
Mr. Peter Ashley Marks
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Brian Derek Meltzer
Mr. Brian Derek Meltzer
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Hannah Howlett
Ms. Hannah Howlett
Investor Relations
Investor Relations
--
--
Mr. Geoffrey Paul Kempler
Mr. Geoffrey Paul Kempler
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Oct 24
Updated: Fri, Oct 24
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Twin Lakes Capital
0.77%
Point72 Asset Management, L.P.
0.73%
Homrich Berg
0.32%
Morgan Stanley & Co. LLC
0.32%
Greenleaf Trust
0.18%
Other
97.69%
Shareholders
Shareholders
Proportion
Twin Lakes Capital
0.77%
Point72 Asset Management, L.P.
0.73%
Homrich Berg
0.32%
Morgan Stanley & Co. LLC
0.32%
Greenleaf Trust
0.18%
Other
97.69%
Shareholder Types
Shareholders
Proportion
Private Equity
0.77%
Hedge Fund
0.73%
Research Firm
0.37%
Investment Advisor/Hedge Fund
0.33%
Bank and Trust
0.18%
Other
97.63%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
27
429.83K
2.37%
+138.63K
2025Q2
25
222.41K
1.45%
+22.59K
2025Q1
25
242.89K
1.60%
+14.64K
2024Q4
25
125.35K
1.13%
-75.38K
2024Q3
25
113.89K
1.28%
-62.37K
2024Q2
24
79.19K
0.91%
-96.76K
2024Q1
24
95.17K
1.09%
-51.08K
2023Q4
23
88.25K
1.89%
-31.21K
2023Q3
26
59.08K
1.45%
-63.37K
2023Q2
27
58.44K
1.44%
-90.15K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Twin Lakes Capital
5.92K
0.03%
--
--
Jun 30, 2025
Point72 Asset Management, L.P.
131.43K
0.73%
--
--
Jun 30, 2025
Homrich Berg
--
0%
-37.48K
-100.00%
Jun 30, 2025
Morgan Stanley & Co. LLC
58.23K
0.32%
+14.60K
+33.46%
Jun 30, 2025
Greenleaf Trust
17.00K
0.09%
+17.00K
--
Jun 30, 2025
BNP Paribas Securities Corp. North America
8.19K
0.05%
-1.56K
-16.02%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.16K
0.01%
--
--
Aug 31, 2025
EverSource Wealth Advisors, LLC
628.00
0%
+628.00
--
Jun 30, 2025
Osaic Holdings, Inc.
181.00
0%
--
--
Jun 30, 2025
Rhumbline Advisers Ltd. Partnership
130.00
0%
--
--
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Dec 30, 2022
Merger
10→1
Dec 30, 2022
Merger
10→1
Dec 30, 2022
Merger
10→1
Dec 30, 2022
Merger
10→1
Date
Type
Ratio
Dec 30, 2022
Merger
10→1
Dec 30, 2022
Merger
10→1
Dec 30, 2022
Merger
10→1
Dec 30, 2022
Merger
10→1
